Immunovant Inc., a clinical-stage immunology company, is under investigation for potential breaches of fiduciary duty by its directors and officers, in connection with a private placement transaction. The investigation focuses on Immunovant's January 2025 transaction, where its controlling stockholder, Roivant Sciences Ltd., purchased approximately 16.9 million shares at $20.00 per share-a $3.48 discount to the prior day's closing price. This discount resulted in a benefit to Roivant of nearly $60 million, raising concerns about the fairness of the deal to other shareholders. The probe invites current Immunovant investors to provide information, emphasizing potential conflicts of interest and shareholder impact.